Searched for
GSK PHARMA NOVARTIS
GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billionGSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includ...- MNC pharma body OPPI appoints Anil Matai as new director generalThe Organisation of Pharmaceutical Producers of India (OPPI) has appointed Anil Matai as its director general. Matai has extensive experien...
- Danone, HUL, KKR vie for GSK’s consumer businessAs per Monday’s market value, 72 per cent of GSK is worth around Rs 17,980 crore.
- Sanofi, Boehringer Ingelheim seek CCI nod for $25-billion global asset swap dealThe commission will review if the two companies swapping their businesses will cause any adverse impact on the local competition.
- GSK Healthcare banks on Sensodyne, Crocin to drive growth in IndiaIn India, the power brands will be Sensodyne, Panadol (called Crocin in India), nasal decongestant Otrivin and Voltaren pain relieving gels...
- Novartis India Q2 net rises over 600% to Rs 104 croreIn April, Novartis had agreed to divest its global Animal Health business to Lilly by transferring it to Elanco India or another affiliate ...
- GSK Pharma trying to find out what ammunition is needed to grow: MDThe Indian arm of British drugmaker GlaxoSmithKline (GSK) is planning a major initiative to wrestle back ground it had conceded.
- GSK Pharma completes deal with Novartis HealthcareDrug firm GlaxoSmithKline Pharmaceuticals has acquired Novartis' vaccines business and divested its marketed oncology portfolio to Novartis...
- Novartis shares up nearly 2% at closeShares of Novartis India ended nearly 2% higher after fair trade regulator CCI approved a multi-billion dollar deal between GlaxoSmithKline...
- Competition Commission of India clears Novartis-GlaxoSmithKline pharma dealThe multi-layered deal involves UK-based GlaxoSmithKline acquiring Novartis's vaccine biz, while latter would purchase GSK's cancer drugs p...
- Novartis India vice-chairman & managing director, Ranjit Shahani says company now focuses on new products, business growthNovartis India has over the past year launched three successful patented drugs and over 12 generic drugs that have helped it expand its pre...
- GSK India to benefit from global business swap deal with NovartisGlaxo will get Novartis’ vaccine portfolio, including anti-rabies products such as Rabipur, while transferring its smaller oncology busines...
- Novartis India rallies over 2% on three way deal with GlaxoSmithKlineGSK will sell its portfolio of cancer drugs to Novartis for $14.5 billion, plus another $1.5 billion, depending on trials in progress, ET r...
- Novartis buys GSK's cancer drugs for $14.5 billion in a 3-way dealThe collaboration between the two will create a new world-leading consumer healthcare business with $10 billion in annual sales.
- Elder Pharma rallies 5% on domestic formulation biz sale talksElder Pharma was locked in upper circuit at Rs 311.05, up 5%. Novartis was trading 0.4% higher at Rs 467, while Sanofi India was down 0.5% ...
- Sanofi, Novartis and GSK in race to buy Elder Pharma's domestic formulations businessSanofi, Novartis and GSK are in the race to buy out the domestic formulations business of debt-ridden Elder Pharmaceuticals.
- Pharma cos shares extend gain on BSEShares of multinational pharmaceutical companies on Wednesday extended gains on the BSE, cheering their parents’ move to hike stake in thes...
- More drug MNCs join the stake-hike bandwagonAfter the two leading pharma multinationals recently increased their stakes in their Indian units, people connected with the industry say t...
- Indian generic companies may tread Ranbaxy pathRanbaxy's patent settlement with Pfizer may lead more Indian generic cos to go for out-of-court settlements with their innovator counterpar...
- Starry show among stars and stripesIn spite of steep pricing pressure and increasing competition, domestic pharma majors, including Ranbaxy Labs, Dr Reddy’s Labs, Cipla and S...
Load More
